Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (4450)	8/10/2001 3:59:36 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 52153

No implications here re. the pathogenesis of axonal damage in MS, as it's (1) not well understood, and (2) less understood by me than most. But....... >> I've seen a claim that both Enbrel and Remicade have poor blood brain barrier permeability. << One needs to remember that TNF initiates activity in cells that can mediate inflammation, and that it also activates the type of cell that constitutes the BBB. Many believe that CD8+ lymphocyte migration into the brain -- cellular infiltration -- plays a role in pathogenesis. I wouldn't assume that peripheral admin of an anti-TNF won't be effective for inflammatory disease in the brain.